RxLedger

Ozempic (Semaglutide) — Medicare Part D spending

Novo Nordisk · Rank #2 by total Part D spend · CMS data year 2023

Medicare Part D spent $9,194,048,435 on Ozempic (Semaglutide) in 2023, the #2 drug by total Part D spending out of 3,598 drugs. That worked out to about $355.90 per dosage unit, $1,327 per claim and $6,278 per beneficiary, across 6,927,972 claims for 1,464,468 beneficiaries. Average spending per dosage unit fell -24.0% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Ozempic (Semaglutide) spending at a glance (2023)

MetricOzempic (Semaglutide)
Total Part D spending (2023)$9,194,048,435
Total spending (2022)$4,628,160,643
Year-over-year change in total spending+98.7%
Average spending per dosage unit (2023)$355.90
Change in spend per dosage unit (YoY)-24.0%
Avg annual change per dosage unit (2019-2023 CAGR)-4.2%
Average spending per claim (2023)$1,327
Average spending per beneficiary (2023)$6,278
Total claims (2023)6,927,972
Beneficiaries (2023)1,464,468
Total dosage units (2023)26,990,261
Manufacturer(s)Novo Nordisk
National rank by total spend (of 3,598 drugs)#2

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Ozempic (Semaglutide): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$4,628,160,643$9,194,048,435+98.7%
Avg spend per dosage unit$468.24$355.90-24.0%
Avg spend per claim$1,357$1,327
Avg spend per beneficiary$5,932$6,278
Total claims3,410,8396,927,972
Beneficiaries780,2531,464,468

How Ozempic compares with nearby drugs

Drugs with total Part D spending closest to Ozempic (Semaglutide):

Ozempic (Semaglutide) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Ozempic (Semaglutide) (this drug, #2)$9,194,048,435$355.90-24.0%
Eliquis (Apixaban) (#1)$18,273,451,967$9.74+6.9%
Jardiance (Empagliflozin) (#3)$8,839,935,063$20.32+4.1%
Trulicity (Dulaglutide) (#4)$7,363,856,224$483.21+5.3%
Xarelto (Rivaroxaban) (#5)$6,309,246,823$18.23+5.6%
Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter) (#6)$4,455,884,010$11.18+3.8%

Frequently asked questions

How much does Medicare Part D spend on Ozempic?

Medicare Part D spent $9,194,048,435 on Ozempic (Semaglutide) in 2023 (the latest CMS data year), across 6,927,972 claims for 1,464,468 beneficiaries. That ranks #2 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Ozempic?

In 2023, the weighted average Medicare Part D spending per dosage unit for Ozempic (Semaglutide) was $355.90. Compared with 2022 it fell -24.0%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Ozempic?

CMS attributes Ozempic (Semaglutide) to Novo Nordisk in the 2023 Part D spending file. Average spending per claim was $1,327 and per beneficiary $6,278.

Is the Ozempic figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20